Respiratory Syncytial Virus Vaccines
Biothervax SpA is involved in clinical research on a recombinant Bacillus Calmette-Guérin platform designed to express the RSV nucleoprotein, with attention to vaccine safety and immune response in older adults.
- RSV immunogenicity
- Recombinant BCG vaccine development
- Viral antigen expression
The research focus includes immune recognition of respiratory syncytial virus antigens in adults over 60 years of age.
Mycobacterial Immunology
The sponsor’s clinical activity also centers on anti-mycobacterial immune responses, comparing cellular immunity elicited by the recombinant vaccine with that of conventional BCG.
- Cellular immune response
- Mycobacterial antigen response
- BCG-based immunology
This area reflects interest in the interaction between vaccine constructs and cell-mediated immunity.
Adult and Geriatric Vaccination
Biothervax SpA’s trial portfolio includes vaccine evaluation in older adults, with a particular emphasis on the immune profile of individuals above 60 years of age.
- Vaccination in older populations
- Age-related immune response
- Preventive immunisation
The clinical interest lies in assessing how vaccine-induced immunity performs in a later-life population.
Infectious Disease Prevention
The sponsor’s research is positioned within preventive infectious disease work, addressing both tuberculosis-related vaccine platforms and protection against RSV.
- Respiratory infection prevention
- Vaccine-based prophylaxis
- Immune protection against viral disease
This creates a focus on vaccines that combine established mycobacterial platforms with added viral antigen targets.
